The submission of a Type C meeting request to the FDA by Oncolytics Biotech is a critical regulatory step, indicating progress in the development of pelareorep for metastatic breast cancer. This development is likely to be viewed positively by investors, as it demonstrates the company's commitment to advancing its pipeline and potentially bringing a new treatment to market. The anticipation of a transformative year with expected overall survival data from the BRACELET-1 study further underscores the potential positive impact on the company's valuation.